Avantra announces Rapid Assay Prototyping Service for researchers and clinicians

Avantra® Biosciences, a leading innovator in protein diagnostics, announces a Rapid Assay Prototyping Service. Avantra's new service allows researchers to cost effectively accelerate their research efforts using custom designed biomarker assays developed on Avantra's proven QPDx™ BioChip platform. The QPDx™ platform offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents.

Avantra's service offering provides researchers and clinicians with rapidly prototyped disease specific biomarker assays. To provide this service, Avantra leverages pre-validated antibody pairs that can be further optimized for specific research needs. In addition, Avantra can design QPDx™ assays that use a client's own immunoassay reagents.  Avantra's assays can be used for screening drug targets, pathway analysis, and disease state biomarker profiling.  

The Avantra Biomarker System is currently being evaluated and used by a variety of health care institutions and research organizations for both research and potential point-of-care applications. This service greatly increases the versatility of the Avantra system providing researchers and clinician's maximum operational efficiencies and reduced costs.